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nanoscaled assembly, specific materials are included 
to provide desired properties such as eluding immune 
recognition, crossing of biological barriers, providing 
contrast in medical imaging, tumor targeting, releasing 
a drug, or delivering gene therapy.[19] In the field of 
neurosurgery, and specifically glioma therapeutics, there 
is great interest, and much skepticism, in the rapidly 
developing application of nanoscaled therapeutics.[18,181] 
Many see nanotechnology as a means to attack glioma 
at its source−the individual mutated genes, tumor stem 
cells, or individual cellular metastases that represent 
barriers to a cure. Materials designed with nanoscopic 
dimensions are able to signal, home, and induce 
damage in a coordinated fashion at the subcellular level, 
permitting an unparalleled degree of control over the 
targeted action of therapeutics.[135]
Glioma arises within the confines of a variably 
intact blood–brain barrier (BBB),[101] is surrounded 
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INTRODUCTION
The ability to manipulate atoms, design supramolecular 
structures, and generate useful function at the nanoscale 
provides exciting opportunities for the treatment of 
human disease. Bionanotechnology is specifically devoted 
to materials possessing sub‑100 nm dimensions, and the 
field possesses an interdisciplinary conceptual breadth 
that can bring practitioners of quantum physics and 
neurosurgery into the same discussion. The fabrication 
of useful architectures, made up of multiple base parts 
each with their own structural or functional role, is 
the overarching principle in most modern biomedical 
applications of nanotechnology.[22,89,158] Discrete molecular 
forces – including chemical bonding, electrostatics, steric 
interaction, and physical adsorption – are often harnessed 
in tandem to generate a 3‑dimensional supramolecular 
layer cake, with an overall function that benefits from 
each of its chemical constituents.[92,100] Within this 
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by functional brain tissue that requires preservation, 
spreads diffusely beyond the gross tumor margin,[55,101] 
is prone to chemotherapy resistance by efflux and 
direct drug inactivation,[147] and can be rapidly lethal. 
The intersection of these obstacles in treatment makes 
glioma a challenging pathological entity, and at the 
same time a worthwhile target for investigation using a 
tailored molecular‑scale approach.[12] Even with current 
optimal treatment, including surgery, chemotherapy, 
and radiation, high‑grade glioblastoma (GBM, WHO 
grade IV) is associated with an average survival of 
12–15 months.[98,160] Progression‑free survival is <24 weeks 
after recurrence,[136,159] and the 5‑year survival is <5%.[49,127] 
As a standard‑of‑care for GBM, radiation therapy is 
known to extend survival approximately 2‑fold,[48,172] and 
the drug temozolomide added to radiation increases 
survival by an additional ~2.5 months.[125,159]
Given the modest treatment benefits of traditional 
therapy, the investigation of nanostructured drug 
formulations has intensified and has profited from 
the significant experience in treatment of non‑glioma 
neoplastic disease.[70,96] The first approval of an 
antineoplastic nanotherapeutic by the US Food and Drug 
Administration (FDA) occurred in 1994 for the treatment 
of acute lymphocytic leukemia (ALL). The drug, 
Oncaspar, was a poly (ethylene glycol) (PEG)‑coated 
L‑asparaginase nanoparticle (NP) that demonstrated 
increased plasma half‑life and decreased immunogenicity 
compared to native L‑asparaginase.[130,142] To date, 
oncaspar remains in clinical use for ALL. A liposomal 
preparation of doxorubicin (Doxil) followed in 1995, 
having been found similarly to increase circulation 
half‑life, and was approved for treatment of Kaposi 
sarcoma.[50,72] Liposomal formulations of vincristine, 
daunorubicin, and cytarabine have been approved for 
clinical use in systemic cancers,[69,144] with liposomal 
cytarabine (DepoCyt) uniquely indicated for intrathecal 
administration in lymphomatous meningitis, and 
currently in phase 1 and 2 trials for central nervous 
system (CNS) metastases from melanoma and breast 
cancer.[27,28]
As illustrated by the examples of Oncaspar and 
DepoCyt, biologically applied nanotechnology has 
utilized the concepts of polymeric[23] and liposomal 
NP systems. Drugs have been successfully loaded to 
the particle surface, and also within the core of both 
of these NPs.[94] Other biologically relevant nanoscaled 
structures include solid lipid NPs,[122,134] metal−polymer 
core‑shell NPs,[89] carbon nanotubes,[195] quantum dots,[71] 
dendrimeric NPs,[7] and virus‑based nanocarriers.[150] 
More complex structures with intriguing names such as 
nanodiamonds[84,182] and nanoworms[2,83] have exploited 
the influence of shape on function. In each of these 
systems, anchoring materials are present and provide a 
base structure, terminal surface groups allow conjugation 
of functional biomolecules, nontoxic polymers help to to 
avoid immunogenicity, degradable materials can provide 
pH‑ or enzyme‑dependent release, and porous materials 
can help load or unload useful compounds.[129] The 
promise of bionanotechnology lies in the vast ability for 
modification; future technologies can be incorporated 
into existing multi‑component constructs with relative 
ease. In our opinion, the application of ultrasmall 
customized therapeutics to glioma treatment will result 
in many further advances applied both in the OR and in 
the clinic. Our discussion here details current progress 
in nanotherapeutics specifically for glioma, and explores 
relevant advances in the field that may ultimately 
transform the current notion of poor prognosis.
TUNABLE NANOMATERIALS FOR GLIOMA 
IMAGING
The ideal nanoscaled imaging agent has the potential 
to cross the BBB and interact with the tumor 
microenvironment, providing detail about a specific 
cellular population of interest. The enhanced permeability 
and retention (EPR) phenomenon of NP accumulation 
within tumors was first reported in the 1980s, and 
nanomaterials were subsequently discovered to traverse 
the intact BBB in 1995.[96,97] Harnessing the EPR effect 
required an approximate size constraint of 30–100 nm. 
Within this regime, NPs would extravasate from poorly 
differentiated neoplastic vessels.[61,146] The slower 
diffusion rate of the particle combined with the limited 
intratumoral lymphatic drainage trapped the particle 
within the tumor mass instead of allowing it to re‑enter 
the systemic circulation.[110,115,178] The EPR accumulation 
of NPs within glioma, as well as macrophage uptake of 
NPs, both facilitate imaging contrast that can persist 
beyond the time when NP has been eliminated from the 
bloodstream.[167]
Nanoscaled materials can be modified to provide 
visualization on conventional imaging modalities. 
Contrast may derive from a magnetic resonance 
(MR)‑ or computed tomography (CT)‑visible metal,[9] 
MR‑active nonmetal (e.g., 19F, 13C),[57] PET‑active 
radioisotope (e.g., 18F, 13N, 11C),[124,131] or chromophore/
fluorophore‑containing biomolecule.[158] Less well‑known 
modalities also benefit from the use of nanomaterials, as 
in photo‑acoustic imaging[174,188] where photon absorption 
(e.g., near‑infrared (NIR) light absorption by gold 
NPs[103] or carbon nanotubes[40]) produces microscopic 
temperature fluctuations in the vicinity of the particle 
and resulting acoustic waves are detected as ultrasound.
For magnetic resonance imaging (MRI), image contrast 
is conveniently generated by the superparamagnetic 
property of certain NPs including those made of iron 
oxide.[157] Superparamagnetism denotes the presence of 
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ultrasmall discrete magnetic domains, which fluctuate 
continuously at rest, but become poled within an 
external magnetic field and act as a coherent strong 
moment.[89,121] While iron oxide NPs historically have 
been used to generate intravoxel signal dephasing, and 
thus darken the appearance of T2‑ and T2*‑weighted 
images, more recent modifications have given iron 
oxide NPs the ability to accelerate T1 relaxation, and 
thus provide “bright” contrast on T1‑weighted scans. 
Such modifications include doping the metal core 
with gadolinium or manganese,[44,68] or manipulation of 
nonmetallic coating size.[150] Figure 1 shows work from 
our own group that highlights the appearance of iron 
oxide NPs in vivo. Gadolinium‑enhanced imaging of an 
orthotopic implanted GBM6 tumor at high magnetic 
field [Figure 1a] is compared with a T2*‑weighted 
image after PEG‑chitosan NP administration, NPs 
highlight the cerebral microvasculature as well as 
tumor [Figure 1b]. These NPs can accumulate in high 
quantities within the tumor yielding contrast as shown 
in a 3‑D reconstruction [Figure 1c]. A photograph of the 
implanted tumor is provided for comparison [Figure 1d].
Nanomaterials have tunable size, hydrophobicity, and 
surface charge [Table 1]. These properties can be 
adjusted to facilitate tumor homing and to avoid rapid 
elimination. NPs with sizes between 15 and 100 nm 
are ideal for ensuring long‑circulation times in blood. 
Below a hydrodynamic size of 10–20 nm, particles will 
be rapidly filtered by the kidneys, and at sizes greater 
than ~150 nm, particles will be sequestered by the 
reticuloendothelial system (RES), with uptake into the 
spleen.[75,178] Although particle uptake by the liver will 
inevitably occur even within this ideal size range, half‑life 
in circulation can remain long (2–40 h).[126] To optimize 
plasma half‑life, Geng et al. constructed tube‑like 
PEG‑poly (caprolactone) micelles with small diameters 
in cylindrical cross‑section (~20 nm), and very large 
cylindrical length (~18 µm).[54] The group found these 
structures would persist in the bloodstream for >5 days 
since they were able to fit lengthwise through tight 
microvascular spaces and were sufficiently long to 
mechanically hinder uptake into macrophages.[54]
Hydrophobic drugs and surfaces are known to be targets 
for opsonization, and modifying a nanomaterial surface to 
be more hydrophilic (e.g., coating with PEG, chitosan, or 
albumin)[108,171] can increase circulation time. Amphiphilic 
molecules such as poloxamer 188 or polysorbate 80 have 
been used to provide the same circulation benefits by 
presenting a hydrophilic surface, while retaining internal 
hydrophobic regions that facilitate entry through the 
brain endothelium.[162,173] Surface charge can be altered 
by incorporating small molecules or polyelectrolytes. 
Positively charged surfaces promote BBB penetration by 
inducing physical adsorption to the endothelium.[107,116] 
In culture, cationic NPs are readily taken up into the 
cells at the periphery of tumor spheres, while anionic 
NPs demonstrate lower intracellular uptake.[90] Curiously, 
Figure 1: In vivo administration of iron oxide nanoparticles. 
(a) Gd-enhanced T1-weighted image and (b) iron oxide NP-enhanced 
T2*-weighted image of mouse glioblastoma tumor (GBM6). (c) 3D 
reconstruction of a T2-weighted image with inverted contrast after 
NP injection. (d) Coronal cross-section photograph of the brain for 
comparison, near the posterior extent of the tumor
dc
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Table 1: Fundamental nanomaterial characteristics and their observed impact on tumor localization
Size (nm) Small Large
<10 <20 <70 <100 >150
Rapid glomerular 
filtration
More easily exits tumor cells 
once internalized (↓ EPR)
Improved convective flow 
through tumor and normal 
brain
Permits 
tumor entry 
via EPR effect
Difficult cell entry 
via endocytosis
Clearance by RES
Hydrophobicity Hydrophilic Amphiphilic Hydrophobic
Increased circulation 
half‑life
Increased BBB penetration Cleared rapidly by 
reticulo‑endothelial system
Surface charge Cationic Uncharged Anionic
Adsorptive‑mediated 
BBB transcytosis;
Reduced charge may facilitate 
spread through tumor ECM
Reduced brain tumor 
cellular uptake in vivo;
Cell membrane 
disruption at high charge
Improved diffusion within 
interstitium
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anionic particles show improved distribution throughout 
the space external to the cells. Zhou and colleagues 
formulated a poly (L‑lysine) NP coated with acid‑labile 
β‑carboxylic amide groups, whose charge switches in the 
presence of acidic tumor microenvironment to exploit 
the apparent diffusive benefits of negative charge with 
the permeability benefits of positive charge.[149,184,198]
The potential to maintain a high plasma concentration 
and interact favorably with the blood−tumor interface 
make NPs highly useful for glioma imaging. Particles 
that can generate contrast on two,[171] or even three[92] 
unique imaging modalities have been constructed, 
with preferential accumulation seen within the 
tumor mass over normal brain. A current human 
clinical trial is in progress, testing the application 
of a magnetite NP coated with polyglucose sorbitol 
carboxymethylether (ferumoxytol) compared with 
standard gadolinium contrast for assessment of BBB 
permeability changes after combination chemotherapy 
in glioma.[29] The study seeks to use the NP as a means 
of calculating tumor blood volume,[26] and to show a 
benefit of the NP in distinguishing pseudo progression 
from tumor recurrence. There has yet to be a human 
clinical trial for imaging using a biochemically targeted 
NP, although such a trial will certainly have value given 
the high affinity of targeted particles for glioma and the 
relatively low toxicity of such materials.[171] Biochemically 
targeted materials will likely be necessary to provide 
uptake in areas with minimal EPR effect as vascular 
permeability may be regionally heterogeneous within 
the glioma mass.[47] In the following section, we discuss 
the role of molecular targeting as it pertains to NP drug 
delivery.
DRUG DELIVERY AND GLIOMA TARGETING
The use of targeted nanomaterials for drug delivery 
has intensified over the past decade.[128] Recent work in 
animal glioma models has used targeted NPs to delay 
tumor growth and improve survival.[62,63,183] A majority of 
research, to date, has utilized orthotopic tumor models 
in mice and rats, including implanted human (e.g., U87, 
T98G, GBM6) and mouse (e.g., C6) cell lines. Transgenic 
murine models of glioma have also been used,[66] and 
although these may not recapitulate human tumor biology 
in the same manner as implanted human cells, they are 
thought to better mimic the tumor microenvironment, 
tumor cell–stroma interactions, and invasive behavior.[43] 
Intracranial murine tumors commonly grow to lethal size 
by ~2 months, and intervention via NP therapeutics is 
usually performed ~1 month after implantation, once 
the tumor has reached intermediate size.[9] Reviewing 
the body of literature, it is common to see successful 
studies in rats and mice with a reported median 
survival increase of ~20 days,[21] with some studies 
demonstrating long‑term remission in a percentage 
of the treated cohort.[155] Given the large number of 
successful animal studies over the past decade, and the 
low reported toxicity of these synthesized materials,[88] 
we expect to see clinical trials soon appear for targeted 
particle systems in glioma. Rigorous testing of short‑ and 
long‑term particle safety will need to be accomplished,[67] 
and more detailed study of particle bio distribution will 
be necessary in large animal models.[117,152] Although a 
great number of laboratories are adept at small‑batch 
NP synthesis, scaling up the synthetic volume and 
maintaining target molecule attachment under 
conditions of clinical‑grade sterility require time and 
funding.[21]
Our optimism with regard to the arrival of clinical trials 
for glioma‑targeted nanotherapeutics is galvanized by 
a number of existing trials for non‑CNS pathology. 
For instance, drug‑carrying liposomes targeted to the 
transferrin receptor are in phase II clinical trials for gastric 
and esophageal adenocarcinoma,[34] and PEGylated 
poly(lactic‑co‑glycolic acid) (PLGA) NPs targeted to 
glutamate carboxypeptidase II are in phase 2 trials for 
multiple solid tumors, including prostate cancer.[30] Toward 
the treatment of recurrent glioblastoma, trials for an 
intravenous nontargeted nanoliposomal formulation of 
the topoisomerase 1 inhibitor irinotecan (CPT‑11) have 
been initiated, with a phase 1 trial currently underway 
for single‑agent therapy.[31] This same agent has shown 
promise when injected intracranially, and a phase 1 trial is 
enrolling patients for convection‑enhanced delivery (CED) 
of CPT‑11 at escalating doses from 20 to 80 mg.[33]
To achieve maximal tumor uptake in vivo, a NP can 
be conjugated to a homing agent that seeks a target 
expressed both on tumor cells and on tumor‑associated 
vascular endothelium. Table 2 presents an alphabetized 
list of the most common homing targets found to 
increase NP uptake in glioma. The table also includes 
a list of popular polymeric coatings, NP configurations, 
and (nongenetic) therapeutic agents used in current 
research.
The targets shown in Table 2 include a number of 
receptors overexpressed on rapidly dividing cells. For 
instance, the transferrin receptor is normally expressed 
on brain endothelial cells, as well as hepatocyte, 
erythroid, and placental cells.[166] In the setting of a brain 
neoplasm, vascular expression of transferrin receptor 
is upregulated.[163] Zhang et al. delivered PEGylated 
immunoliposomes past the BBB to mice bearing U87 
glioma xenografts via targeting antibodies that bound 
transferrin and insulin receptors.[194] Further research 
with insulin receptor targeting alone also resulted in 
increased NP accumulation.[164] Expression of the folic 
acid receptor at the BBB has been found to facilitate 
brain entry of drug‑loaded targeted NPs,[79] and 
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Table 2: Example homing targets, polymeric coatings, 
nanoparticle configurations, and therapeutic agents 
utilized in nanoparticle drug delivery for glioma
Nanoparticle homing targets in Glioma
Diptheria toxin receptor 
(via CRM197)
EGFR Fibrin (via CREKA peptide)
Folate receptor
IL‑13 receptor
Insulin receptor
Laminin
LDL receptor
LRP (LDL receptor‑related protein)
Mitochondria 
(via CGKRK peptide)
MMP‑2/annexin A2 (via chlorotoxin)
Nucleolin
Target of RVG29
Target of HIV TaT peptide
Transferrin receptor
Vascular integrin αVβ3 
(via RGD peptide)
Polymers
Alginate
Chitosan
CSA (cationic serum albumin)
Gelatin
PAMAM Poly (amidoamine)
PBAE Poly (β‑amino ester)
PBCA poly (butylcyanoacrylate)
PCL poly (ε‑ caprolactone)
PEG poly (ethylene glycol)
PLA poly (lactic acid)
PLGA poly (lactide‑co‑glycolide)
PS polystyrene
Nanoparticle Configurations Therapeutic Agents
Dendrimeric
DNA/RNA‑based
Lipid‑based
Metallic core‑shell
Micellar
Polymer aggregate
Viral‑based
Doxorubicin/Epirubicin
Etoposide
Irinotecan
Methotrexate
Paclitaxel
Temozolomide
Pro‑apoptotic peptides
targeting of epidermal growth factor receptor (EGFR) 
overexpression on intracranial U87 tumors has similarly 
facilitated antineoplastic activity, with encapsulated 
chemotherapeutics delivered both intravenously[114] 
and via CED.[63] A related EGF peptide known as 
heparin‑binding EGF‑like growth factor (HB‑EGF) has 
been discovered on the endothelial surface, and is known 
to bind diphtheria toxin.[51] The use of mutated nontoxic 
formulations of diphtheria toxin has correspondingly been 
shown to facilitate BBB crossing.[52] Conjugation of IL‑13 
to liposomes has increased drug transport to intracranial 
U251 implants as glioma cells overexpress the IL‑13 
receptor α2.[109] More esoteric receptor‑targeting strategies 
have also shown promising results in glioma, such as 
the conjugation of rabies virus glycoprotein 29 (RVG29) 
peptides to dendrimeric NPs.[106] The increased brain 
uptake was attributed to binding of RVG29 to GABAB 
or nicotinic acetylcholine receptors.[106] A final popular 
target is the overexpressed low density lipoprotein (LDL) 
receptor, although LDL receptor‑related proteins (LRP) 
also function well for targeting. While NP coating 
with agents including apoE or polysorbate 80 have 
induced binding to the LDL receptor,[95] attachment of 
β‑amyloid precursor protein has resulted in binding to 
LRP.[93] LRP has been found both on glioma cells and 
BBB endothelium, with specific intracranial targeting and 
drug delivery having been demonstrated in a mouse U87 
model.[41,183]
Similar to the case of LRP, other nonantibody proteins 
are overexpressed by glioma and appear in detectable 
quantities on the endothelium of tumor vessels. 
Examples include laminin 411,[42] nucleolin,[46] and 
fibrin.[25] The penta‑peptide CREKA (cysteine−
arginine−glutamic acid−lysine−alanine) was chosen 
with specific binding affinity for fibrin, and was found to 
yield particle deposition within GBM tumors 1 h after IV 
injection.[25] Other successful examples of short peptide 
binding include the tri‑peptide RGD (arginine−glycine−
aspartic acid) that binds to αVβ3 integrin on immature 
endothelial cells,[10,20] and the penta‑peptide CGKRK 
(cysteine−glycine−lysine−arginine−lysine) that binds to 
heparan sulfate on tumor endothelium.[2]
The 36‑amino acid peptide chlorotoxin (CTX) has 
been the subject of much focused research.[88,89,168,169] 
CTX is derived from the venom of the scorpion Leiurus 
quinquestriatus, and can facilitate NP entry across 
the BBB into tumor cells via binding of overexpressed 
matrix metalloproteinase‑2 and annexin A2.[86] Figure 2 
demonstrates accumulation of fluorescently labeled 
CTX‑conjugated iron oxide NPs within a GFP expressing 
C6 glioma xenograft, by ex vivo fluorescence imaging, 
histology/iron staining, and detection of fluorescent label 
within individual cells.
While NPs are typically thought of as passive smart 
delivery vehicles, they can also be engineered to actively 
move throughout the tumor. Recent work has opened up 
the possibility to engineer NPs that migrate throughout 
the tumor with targeting agents that “walk” along antigen 
receptors.[132] Cells can also be used as delivery vehicles 
for NPs to provide active migration to and throughout the 
tumor. Microglia have been used for such a purpose as 
they are chemo attracted to brain tumors.[138,139] Neuronal 
stem cells (NSCs) have been used as delivery vehicles 
for glioma; NSCs have high specificity to brain tumor 
tissue and are able to actively move throughout the 
tumor.[1] The majority of this work has been performed 
using NSCs engineered to express oncolytic viruses 
or tumor suppressor proteins.[140] Importantly, NSCs 
can be loaded with NPs without affecting their normal 
cellular function and can be tracked using MRI.[14] We 
foresee NSCs being used as a Trojan horse to deliver 
multifunctional NPs to gliomas. The ability to track 
NSCs, as well as engineered T cells[13] and dendritic cells[6] 
for immunotherapy[137] when loaded with NPs will provide 
a more useful platform for optimizing these therapies. 
Imaging data could reveal if a therapeutic response is 
correlated with successful accumulation of cells in the 
tumor and with appropriate tumor eradication.
NANOPARTICLE GENE THERAPY
Nanotechnology provides tools to overcome current 
limitations in nonviral glioma gene delivery, and we 
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believe that nanomaterial‑facilitated gene therapy 
will eventually be incorporated into routine glioma 
management. Avenues of gene therapy for glioma 
include: (i) replacement of damaged genes with 
functional counterparts, (ii) knockdown of proteins 
required for glioma cell survival using small interfering 
RNAs (siRNAs) or short hairpin RNAs (shRNAs), 
(iii) delivery of genes that code for enzymes that 
convert inert prodrugs into cytotoxic compounds, 
and (iv) modulation of the stromal compartment by 
inhibiting angiogenesis or activation of the immune 
system. Gene therapy offers significant advantages 
over small‑molecule drugs, as many targets are 
currently “undruggable” with existing therapeutics.[176] 
Furthermore, genetic therapies may facilitate key cellular 
transformations such as terminal differentiation of brain 
tumor stem cells.[162] The translation of gene therapies 
into the clinic has been hindered by the lack of a safe 
and effective gene delivery vehicle. Most clinical trials 
utilize viral vectors as they are effective at transferring 
genetic material into target cells. However, systemically 
administered viral gene transfection is limited by a 
rapid clearance rate due to recognition by the immune 
system and lack of tumor penetration caused by their 
large size (~100 nm).[99]
NPs have been proven capable of binding and protecting 
a nucleic acid payload. This was achieved initially by 
encapsulating nucleic acids into liposomes. The surface 
of the liposome can be modified with targeting and 
imaging agents with the nucleic acid protected in the 
liposome core. An early‑adopted DNA gene therapy 
utilized liposomes to deliver a suicide gene, herpes 
simplex virus thymidine kinase, along with ganciclovir 
as the prodrug.[37] Cationic liposomes were also used to 
deliver the gene encoding interferon‑β (IFN‑β). Results in 
mice prompted a limited human trial using intratumoral 
injection of this formulation in five patients, with two 
glioma tumors demonstrating growth arrest for 10 weeks, 
and two others showing size reduction that persisted 
for ~16 months.[187] However, to date, this drug has not 
progressed past stage 1 clinical trials.
In addition to lipid particles, cationic polymer or 
core‑shell NPs may also bind negatively charged 
nucleic acids through electrostatic interaction, and the 
condensation of these nucleic acids into the polymer layer 
may provide them with a means of protection. Nucleic 
acid protection can be challenging in complex fluids 
such as blood, where particle aggregation or nonspecific 
binding of serum proteins and cells can occur. To further 
protect nucleic acids, NPs can be stabilized through 
coating with PEG[133,193] or zwitterionic polymers[185] that 
create a hydration layer surrounding the NP. A particle 
designed in this fashion delivered tumor necrosis 
factor related apoptosis inducing ligand (TRAIL) by 
encapsulation within PEG/PLA NPs. TRAIL induces cell 
death in glioma cells that have the appropriate receptors 
overexpressed on their surface.[189]
More recently, significant focus has been placed 
on siRNA delivery to knockdown expression of 
genes required for glioma cell survival.[170] Cationic 
liposome‑mediated delivery of c‑Met siRNA decreased 
c‑Met expression in orthotopic glioblastoma tumors in 
mice, and suppressed tumor growth.[76] Effective delivery 
of siRNA against EGFR was also demonstrated, both 
with intravenous liposomal delivery to a subcutaneous 
implanted U251 glioma model,[81] and by attachment 
Figure 2: Targeting of iron oxide nanoparticles to orthotopic C6 glioma xenograft tumors in mice. (a) IVIS bioluminescent imaging of 
luciferase signal demonstrates tumor location. (b) Fluorescence imaging of red channel (710 nm) shows concentrated presence of cy5.5 
fluorophore-labeled NPs within the glioma mass. (c) Hemotoxylin and eosin, and (d) prussian blue/nuclear fast red stained sections of 
the tumor show accumulation of iron oxide 24 h after injection. (e) Fluorescence microscopy of C6 cells loaded with CTX/cy5.5-bound 
NPs in vitro
d
c
b
a e
 SNI: Neuro-Oncology 2015,  Vol 6, Suppl 1 - A Supplement to Surgical Neurology International
S51
to crosslinked dendrimeric iron oxide NPs followed by 
intracranial delivery to a transgenic glioma model.[3] 
Modified siRNAs have also been constructed that are 
protected from nuclease degradation and are readily 
taken up into cells.[24,85,177,180] These modified siRNAs 
provide the opportunity to focus NP engineering 
strategies away from siRNA protection and toward 
prolonging circulation time, increasing site‑specific 
delivery, and promoting distribution throughout the 
tumor. By reducing the design constrains on NPs, we 
may thus simplify their construction and accelerate 
clinical translation.
On the horizon are exciting gene therapies whose 
application to glioma may be facilitated by nanoscaled 
delivery agents. For instance, spherical nucleic acid NP 
conjugates have been constructed from gold NPs coated 
in a densely packed, highly oriented layer of siRNA. 
These structures have been found to be well protected 
from nuclease degradation and provide highly efficient 
knockdown.[74,141] Clustered regularly interspaced short 
palindromic repeats (CRISPR)/Cas9 technology has 
quickly become a mainstream tool to regulate gene 
expression.[35,113,143] A Cas9 nuclease attached to an 
RNA guide makes a double‑strand break at the RNA 
target sequence in the genome. Modified Cas9 can also 
induce DNA base methylation, chromatin modification, 
and even activation of gene expression. RNA 
activation (RNAa) also allows control of gene expression, 
and to date it has been less widely adopted.[73,82,102] 
Using RNAa, double‑stranded ribonucleotide segments 
are delivered, which interact with the promoter region 
of a gene to induce expression, providing a means to 
reactivate tumor suppressor genes without the need to 
deliver the entire coding sequence.
Human clinical trials have shown some success with NP 
siRNA delivery, indicating the approach may soon be a 
viable option for glioma.[38] We are currently at a point 
where the library of known glioma targeting agents is 
progressively being applied to the transport of genetic 
material in small animal models. The targeting agents 
can facilitate trafficking not only to the glioma cell 
itself, but also to the nucleus or perinuclear region. NPs 
targeted with the peptide chlorotoxin, for instance, were 
found to promote localization in the perinuclear region 
with resulting high transfection efficiencies.[87,88] Genetic 
therapy in glioma is likely to yield optimum benefit as 
part of a combined treatment strategy. The use of gene 
therapy via NPs, in combination with chemotherapy drugs 
attached to the particle, could provide maximal benefit 
due to the co‑localization of therapy. As we will discuss 
next, the third arm of a combined future treatment 
strategy can be tumor ablation using ingeniously applied 
chemistry and biophysics, to promote energy deposition 
at the site of the NP.
NANOMATERIAL TISSUE ABLATION−
CREATIVE APPROACHES TO 
NANONEUROSURGERY
Successful NP drug or gene delivery must adhere to 
a delicate chemical and biological scheme including: 
(i) strong attachment of the therapeutic payload in high 
quantities, (ii) guarding of the beneficial agent from 
detachment in the bloodstream, (iii) carrying of the drug 
or gene into the tumor, and (iv) release of the payload 
once inside the cell. The chemistry of NP design often 
involves a limited number of competing reactive sites to 
attach drug and targeting agent, making the addition of 
both at appropriate quantity a challenge. In contrast, it is 
conceptually less complex to design a NP, which simply 
delivers itself to a glioma mass. Once internalized, NPs 
can be “activated” from outside the body in a number 
of ways−including photons and magnetic fields−causing 
them to release energy and ablate tissue with a level of 
precision that is determined by their targeting efficiency. 
The particles are otherwise biocompatible and nontoxic 
to cells, until the external trigger is initiated. If delivered 
appropriately, particles can accomplish selective tumor 
destruction, with no entry tract and minimal off‑target 
tissue damage. Such a nanosurgical approach could prove 
of great value especially for the treatment of deeply 
situated glioma, in which location makes conventional 
surgery counterproductive.
The interaction between externally applied photons and 
an internalized material was the conceptual basis of 
photodynamic therapy (PDT) − a principle first described 
over 100 years ago.[120] Embedded photosensitizers were 
found to generate singlet oxygen (1O2) when excited 
with the appropriate wavelength, and would result in free 
radical damage at a distance of ~100 nm.[119] The visible 
light‑activated (630 nm) compounds porfimer sodium 
and 5‑aminolevulinic acid are well known examples of 
photodynamic agents. Porfimir sodium is in clinical use 
for nonsmall cell lung cancer and esophageal cancer,[80] 
and is also in clinical trials for glioma.[32] PDT has been 
under investigation for neurosurgical purposes for over 
two decades, and photoactivators have many novel 
applications through their incorporation into nanoscaled 
materials.[8] Santos et al. recently injected single‑walled 
carbon nanotubes into murine temozolomide‑resistant 
glioma flank tumors. These nanotubes absorb NIR light 
from an external laser source without the need for an 
additional photoactivator, resulting in radiative relaxation 
and hyperthermic tumor ablation.[145] A similar concept 
has been demonstrated for intracranial tumors using an 
external NIR source that interacts with hybrid silica‑gold 
nanoshells.[39] Direct neurosurgical investigation of 
this technology is currently expanding, with lasers 
positioned either adjacent to an open resection cavity, 
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or intracranially using long needles similar to those for 
laser‑induced interstitial thermotherapy (LITT).[161,190] 
Particles can either be injected intravenously or directly 
into the brain using the principles of CED.[5,11]
NPs can also interact with photons outside the UV‑visible 
infrared region of the electromagnetic spectrum, and can 
increase the tissue‑ablating potential of very low frequencies. 
In the radiofrequency (RF) regime, shortwave (13.56 MHz) 
RF fields emitted at low power will induce negligible 
damage to tissues on their own.[53] When these RF waves 
encounter an electron‑dense nanomaterial (e.g., metallic 
NP, carbon nanotube, quantum dot), the vibrational 
energy release from RF‑induced electron movement can 
result in amplified resistive heating, which occurs on 
a length scale of ~100 µm around the particle.[58] The 
NPs effectively focus the energy from the broadly applied 
RF field onto specific sites of interest. Heating at these 
microscale dimensions can occur at a rate of 1–3°C/s, with 
local boiling temperatures attainable within minutes.[58,59] 
This is in contrast to standard RF ablation, which involves 
higher delivered power, and damages bulk tissue within 
a radius of 2–4 cm from a probe tip.While standard RF 
abliation has been involved in human clinical trials for 
glioma,[45,179] and although applications of targetted NP−
RF ablation have been successfully demonstrated in animal 
models of nonglioma neoplasms,[16,60] further investigation 
using targetted RF nanotherapeutics for glioma is currently 
warranted.
Within the high‑frequency spectral range, X‑ and 
gamma‑rays are known to interact with metalic NPs, 
especially those composed of metals having a high 
atomic number.[36] When high‑energy photons encounter 
an appropriate electron‑dense heavy metal, they yield a 
localized deposition of energy due to inner‑shell electron 
transitions in the metal atom, followed by relaxation 
and local emission of photons and electrons from the 
metal itself (Auger effect).[36,123] This electron cascade 
then triggers free radical formation in the surrounding 
solution, which can damage DNA, cell membranes, or 
cellular machinery. As perceived by the involved tumor 
cells receiving radiation damage, this spatially localized 
deposition of X‑ or gamma‑rays energy acts similar 
to the high linear energy transfer (LET) behavior of 
particle radiation.[17] Although this effect also occurs with 
individual metal atoms, the NP delivery scheme provides a 
biocompatible polymer coating and prevents toxicity of the 
metal.[192] Success has been achieved with this approach 
using NPs composed of silver[105] and gadolinium,[36] 
although the most widely adopted material in this respect 
has been gold.[4,15,64] Hainfeld et al. demonstrated good 
response of intracranial Tu‑2449 × enograft gliomas to 30 
and 35 Gy doses of 100 kVp X‑rays, administered in the 
presence of nontargeted gold NPs.[65] In this study, 5 of 9 
mice remained alive one year after treatment, compared 
with 2 of 11 mice in the radiation‑only group. Combined 
technologies have also been described, such as the 
self‑lighting PDT technique.[19] In this method, ionizing 
radiation is applied externally to activate photon release 
from a scintillation‑luminescent NP. Visible light produced 
by the particle then activates adjacent PDT‑active 
photosensitizers, accomplishing the 1O2‑dependent action 
of PDT, and circumventing the problem of visible light 
penetration through biological tissue.
Despite the body of research using photons to activate 
biologically internalized NPs, perhaps the greatest 
progress in external manipulation of NPs has been 
with magnetic fields.[151] Magnetic materials, including 
NPs of appropriate composition, undergo magnetic 
moment hysteresis and enhanced Brownian motion 
when subjected to a rapidly alternating field.[77,151,175] 
These effects contribute to thermal energy release 
and result in localized heating. The principles of 
magnetic hyperthermia have been under investigation 
for over 60 years,[56] and the first applications of this 
technology for treatment of glioma were initiated 
in the late 1980s by Stea et al., using ferromagnetic 
seeds.[153,154] A wide range of preclinical studies in 
animals have demonstrated significant survival benefit 
in glioma when using superparamagnetic iron oxide 
NPs followed by magnetic hyperthermia.[78,104,186] This 
success prompted human clinical trials based in 
Germany using an aminosilane‑coated iron oxide NP, 
with magnetic thermotherapy added to conventional 
treatment. The first results were published in 2007,[77,111] 
and the most recent were published in 2011.[112,165] 
The combined therapy yielded an average survival 
of 13.4 months after glioma recurrence, in a cohort 
of 59 patients. Comparison against a conventional 
treatment cohort with comparable tumor size and 
demographics showed a survival of 6.2 months 
after recurrence. The study selected patients with 
supratentorial GBM, up to 3 foci, a maximum tumor 
size of 7 cm, and a Karnofsky score >60 at the time 
of enrollment. NPs were delivered to the tumor through 
direct intracranial injection (concentration 112 mg/ml) 
of ~4.5 ml of solution, and were exposed to a magnetic 
field alternating at 100 kHz. Transient intratumoral 
temperatures of approximately 51°C were reached. 
Figure 3 displays representative CT‑based maps of NP 
after instillation for this therapy. After postmortem 
study of relevant brain tissue, the authors concluded 
that magnetic heating contributed to additional 
coagulative necrosis in the areas containing the NP.[165]
TOWARD A CURE−NANOTECHNOLOGY IN 
THE OPERATING ROOM AND IN THE CLINIC
The methods of NP tissue ablation and of NP drug−
gene delivery, when viewed together, provide a glimpse 
of the great potential that nanotechnology has in 
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the field of glioma. To date, the literature on these 
approaches has remained discrete, and the presence of an 
integrated literature exploring the potential of combined 
targeting, molecular therapeutics, and photon/magnetic 
ablation remain in the formative stages. Rather than 
simply allowing treatment through a single modality, 
nanotechnology can act as a platform for multi‑modal 
glioma treatment, employing many useful approaches 
simultaneously. We envision a treatment scheme that 
incorporates a number of therapeutic strategies via a 
common nanoscaled agent for targeted delivery.
Over the past decade, there has been much speculation 
with regard to the “theranostic” potential of NP 
materials. Utilizing a single vehicle to assist in both 
diagnosis and treatment brings the worlds of clinic and 
the operating room closer together. It also brings exciting 
principles of physics and spectroscopy closer to the 
direct management of glioma. From a purely conjectural 
standpoint, we reflect on a hypothetical particle that is 
injected intraoperatively after resection, with magnets 
closely positioned around the resection cavity to draw 
iron oxide NP quickly to the margins of the tumor 
bed.[191,196] Such a NP would carry one or more molecular 
targeting agents to promote internalization past the BBB 
and to the tumor cell nucleus. After surgery, based on the 
estimated degree of successful NP delivery−as gauged by 
the superparamagnetic signature on MRI−radiation dose 
for NP‑enhanced ionizing‑beam therapy could be chosen. 
Such therapy would act synergistically with the otherwise 
prohibitively hydrophobic chemotherapeutic drug that 
was simultaneously bound to the particle.
A second, and separate, hypothetical scenario involves 
the treatment of gliomas that are poor candidates for 
resection due to deep intracerebral location. In this 
setting of highly sensitive surrounding anatomy, CED 
of the NP formulation (potentially performed at the 
same time as stereotactic biopsy) would be followed by 
imaging to confirm the absence of off‑target particle 
diffusion (e.g., to the brainstem or near large cerebral 
vasculature). Subsequently, magnetic convective heating 
would be applied, and would act along with the combined 
action of oral chemotherapy and NP‑bound gene therapy.
Such hypothetical combined therapeutic strategies may 
soon present viable options for clinical testing.[197] One 
concept explored by Karabeber et al. used NPs coated with 
a Raman‑active 4,4′‑bipyridine dye loaded in between a 
gold core and a silica outer shell.[83,92] The group performed 
a sequential resection of tumor in an infiltrative glioma 
model, while applying a handheld surface‑enhanced 
Raman scattering (SERS) probe to determine if neoplastic 
cells remained at the margins [Figure 4]. The study 
found that resection of all Raman‑active microscopic 
tumor foci resulted in the absence of local tumor cells 
on follow‑up immunohistochemistry. The NPs, in this 
example provided intraoperative feedback with cellular 
precision. Another example from Veiseh et al. described 
a dual MR‑ and NIR‑active NP, targeted with chlorotoxin 
to pass the BBB.[171] This same particle has been recently 
conjugated with O6‑benzylguanine and injected directly 
into GBM6 gliomas, with excellent visualization on MRI, 
minimal off‑target toxicity, and demonstration of survival 
benefit.[156]
A schematic of our idealized future nanotherapeutic 
incorporating a number of the features described above 
is displayed in Figure 5. The field of nanotechnology 
Figure 3: Human intratumoral injection of iron oxide NP, for clinical 
study of magnetic hyperthermia. (a) Coronal CT image displays 
hyperdense NP mass, with surrounding isothermic lines of simulated 
treatment temperatures (red=50°C, blue=40°C). (b) Fused CT–MRI 
images showing enhancing glioma margin (brown), with respect 
to the iron oxide infusion (purple). Adapted with permission from 
Maier-Hauff et al.[112]
Figure 4: Intraoperative spectroscopy. A handheld SERS probe 
assisted in optimizing surgical resection of infiltrative glioma 
from the brain of a mouse, after Raman-active nanoparticles were 
delivered intravenously. Tumor site before (a and b) and after 
(c) resection are displayed, as well as a schematic of the handheld 
probe in use (d), and an example spectrum of the particle detected 
in cells at the tumor margin (e). Adapted with permission from 
Karabeber et al.[83]
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provides an array of options for the improved diagnosis 
and treatment of glioma. The principles of smart 
molecular design allow us to choose simultaneous 
treatment strategies that work synergistically to eradicate 
tumor cells both within the enhancing margin and 
beyond. The existing body of work and current clinical 
trials suggest that such combined therapeutic strategies 
will likely be ready for clinical testing within the next 
5–10 years. Rather than a substitute for surgical therapy, 
nanoscaled treatment modalities provide an adjunct 
to modern surgical strategies−improving the extent of 
resection, working noninvasively to eradicate tumor cells 
remaining after surgery, and targeting the biomolecular 
mechanisms that make glioma a challenging neoplasm.
REFERENCES
1. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, et al. Neural stem 
cells display extensive tropism for pathology in adult brain: Evidence from 
intracranial gliomas. Proc Natl Acad Sci U S A 2000;97:12846‑51.
2. Agemy L, Friedmann‑Morvinski D, Kotamraju VR, Roth L, Sugahara KN, 
Girard OM, et al. Targeted nanoparticle enhanced proapoptotic peptide as 
potential therapy for glioblastoma. Proc Natl Acad Sci U S A 2011;108:17450‑5.
3. Agrawal A, Min DH, Singh N, Zhu H, Birjiniuk A, von Maltzahn G, et al. Functional 
delivery of siRNA in mice using dendriworms. ACS Nano 2009;3:2495‑504.
4. Al Zaki A, Joh D, Cheng Z, De Barros AL, Kao G, Dorsey J, et al. Gold‑loaded 
polymeric micelles for computed tomography‑guided radiation therapy 
treatment and radiosensitization. ACS Nano 2014;8:104‑12.
5. Allard E, Passirani C, Benoit JP. Convection‑enhanced delivery of nanocarriers 
for the treatment of brain tumors. Biomaterials 2009;30:2302‑18.
6. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of 
dendritic cells for cancer therapy. Lancet Oncol 2014;15:E257‑67.
7.	 Bai	CZ,	Choi	S,	Nam	K,	An	S,	Park	JS.	Arginine	modified	PAMAM	dendrimer	for	
interferon beta gene delivery to malignant glioma. Int J Pharm 2013;445:79‑87.
8. Bechet D, Couleaud P, Frochot C, Viriot ML, Guillemin F, Barberi‑Heyob M. 
Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends 
Biotechnol 2008;26:612‑21.
9. Bhojani MS, Van Dort M, Rehemtulla A, Ross BD. Targeted imaging and therapy 
of brain cancer using theranostic nanoparticles. Mol Pharm 2010;7:1921‑9.
10. Bibby DC, Talmadge JE, Dalal MK, Kurz SG, Chytil KM, Barry SE, et al. 
Pharmacokinetics and biodistribution of RGD‑targeted doxorubicin‑loaded 
nanoparticles in tumor‑bearing mice. Int J Pharm 2005;293:281‑90.
11.	 Bobo	RH,	 Laske	DW,	Akbasak	A,	Morrison	 PF,	Dedrick	 RL,	Oldfield	 EH.	
Convection‑enhanced delivery of macromolecules in the brain. Proc Natl 
Acad Sci U S A 1994;91:2076‑80.
12. Brandsma D, van den Bent MJ. Molecular targeted therapies and chemotherapy 
in malignant gliomas. Curr Opin Oncol 2007;19:598‑605.
13. Brown CE, Starr R, Martinez C, Aguilar B, D’Apuzzo M, Todorov I, et al. 
Recognition and Killing of Brain Tumor Stem‑Like Initiating Cells by CD8(+) 
Cytolytic T Cells. Cancer Res 2009;69:8886‑93.
14. Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, et al. 
Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking 
of stem cells. Nat Biotechnol 2001;19:1141‑7.
15. Burger N, Biswas A, Barzan D, Kirchner A, Hosser H, Hausmann M, et al. 
A	method	for	the	efficient	cellular	uptake	and	retention	of	small	modified	
gold nanoparticles for the radiosensitization of cells. Nanomedicine 
2014;10:1365‑73.
16. Cardinal J, Klune JR, Chory E, Jeyabalan G, Kanzius JS, Nalesnik M, et al. 
Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. 
Surgery 2008;144:125‑32.
17. Carter JD, Cheng NN, Qu Y, Suarez GD, Guo T. Nanoscale energy deposition 
by X‑ray absorbing nanostructures. J Phys Chem B 2007;111:11622‑5.
18. Caruso G, Caffo M, Alafaci C, Raudino G, Cafarella D, Lucerna S, et al. Could 
nanoparticle systems have a role in the treatment of cerebral gliomas? 
Nanomedicine 2011;7:744‑52.
19. Chen W, Zhang J. Using nanoparticles to enable simultaneous radiation 
and photodynamic therapies for cancer treatment. J Nanosci Nanotechnol 
2006;6:1159‑66.
20. Chen X, Plasencia C, Hou Y, Neamati N. Synthesis and biological evaluation 
of dimeric RGD peptide‑paclitaxel conjugate as a model for integrin‑targeted 
drug delivery. J Med Chem 2005;48:1098‑106.
21.	 Cheng	Y,	Morshed	RA,	Auffinger	B,	Tobias	AL,	Lesniak	MS.	Multifunctional	
nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev 
2014;66:42‑57.
22. Chertok B, Webber MJ, Succi MD, Langer R. Drug delivery interfaces in the 
21st	century:	From	science	fiction	ideas	to	viable	technologies.	Mol	Pharm	
2013;10:3531‑43.
23. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, et al. A phase I study 
of a 2‑day lapatinib chemosensitization pulse preceding nanoparticle 
albumin‑bound Paclitaxel for advanced solid malignancies. Clin Cancer Res 
2009;15:5569‑75.
24.	 Chiu	YL,	Rana	TM.	siRNA	function	in	RNAi:	A	chemical	modification	analysis.	
RNA 2003;9:1034‑48.
25. Chung EJ, Cheng Y, Morshed R, Nord K, Han Y, Wegscheid ML, et al. 
Fibrin‑binding, peptide amphiphile micelles for targeting glioblastoma. 
Biomaterials 2014;35:1249‑56.
26. ClinicalTrials.gov. Assessing Dynamic Magnetic Resonance (MR) Imaging 
in Patients With Recurrent High Grade Glioma Receiving Chemotherapy. 
Available from: http://clinicaltrials.gov/ct2/show/NCT00769093; [Last 
accessed on 2014 Aug 01].
27.	 ClinicalTrials.gov.	A	Clinical	Trial	 to	Assess	 the	 Safety	 and	 Efficacy	 of	 the	
Treatment of Patients With Metastasis From Malignant Melanoma‑Treatment 
Consists of the Substances Lomustine (Capsules) and Cytarabine (Injected 
Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the 
Brain. Available from: http://clinicaltrials.gov/show/NCT01563614; [Last 
accessed on 2014 Aug 01].
28. Cl inicalTrials .gov. Intrathecal Chemotherapy With Liposomal 
Cytarabine (DepoCyte®) in Leptomeningeal Metastases of Breast Cancer 
Versus no Intrathecal Treatment. Available from: http://clinicaltrials.gov/ct2/
show/NCT01645839; [Last accessed on 2014 Aug 01].
29. ClinicalTrials.gov. Magnetic Resonance (MR) Imaging Study Using Ferumoxytol 
to Assess Early Tumor Response in Patients With Glioblastoma Multiforme 
Available from: http://clinicaltrials.gov/ct2/show/NCT00660543; [Last 
accessed on 2014 Aug 01].
30.	 ClinicalTrials.gov.	A	Phase	2	Study	to	Determine	the	Safety	and	Efficacy	of	
BIND‑014 (Docetaxel Nanoparticles for Injectable Suspension), Administered 
to Patients With Metastatic Castration‑Resistant Prostate Cancer. Available 
from: http://clinicaltrials.gov/ct2/show/NCT01812746; [Last accessed on 
2014 Aug 01].
31. ClinicalTrials.gov. A Phase I Trial of Nanoliposomal CPT‑11 (NL CPT‑11) 
in Patients With Recurrent High‑Grade Gliomas. Available from: http://
clinicaltrials.gov/ct2/show/NCT00734682; [Last accessed on 2014 Aug 01].
Figure 5: Conceptualized ideal nanoparticle. A metal core is used 
for image contrast and radiation/magnetic therapy, while the 
polymeric shell provides biocompatibility and functional sites for 
attachment of homing molecules, nucleic acids, chemotherapeutics, 
and optically active moieties
 SNI: Neuro-Oncology 2015,  Vol 6, Suppl 1 - A Supplement to Surgical Neurology International
S55
32. ClinicalTrials.gov. Photodynamic Therapy (PDT) for Brain Tumors. Available 
from http://clinicaltrials.gov/ct2/show/NCT01682746; [Last accessed on 
2014 Aug 01].
33. ClinicalTrials.gov. Study of Convection‑Enhanced, Image‑Assisted Delivery of 
Liposomal‑Irinotecan In Recurrent High Grade Glioma. Available from: http://
clinicaltrials.gov/ct2/show/NCT02022644; [Last accessed on 2014 Aug 01].
34. ClinicalTrials.gov. Study of MBP‑426 in Patients With Second Line Gastric, 
Gastroesophageal, or Esophageal Adenocarcinoma. Available from: http://
clinicaltrials.gov/ct2/show/NCT00964080; ]. [Last accessed on 2014 Augt 01].
35. Cong L, Ran FA, Cox D, Lin SL, Barretto R, Habib N, et al. Multiplex Genome 
Engineering Using CRISPR/Cas Systems. Science 2013;339:819‑23.
36. Coulter JA, Hyland WB, Nicol J, Currell FJ. Radiosensitising nanoparticles 
as novel cancer therapeutics‑‑pipe dream or realistic prospect? Clin Oncol 
2013;25:593‑603.
37. David S, Montier T, Carmoy N, Resnier P, Clavreul A, Mevel M, et al. Treatment 
efficacy	of	DNA	lipid	nanocapsules	and	DNA	multimodular	systems	after	
systemic administration in a human glioma model. J Gene Med 2012;14:769‑75.
38. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. 
Evidence of RNAi in humans from systemically administered siRNA via 
targeted nanoparticles. Nature 2010;464:1067‑70.
39. Day ES, Thompson PA, Zhang L, Lewinski NA, Ahmed N, Drezek RA, et al. 
Nanoshell‑mediated photothermal therapy improves survival in a murine 
glioma model. J Neurooncol 2011;104:55‑63.
40. De la Zerda A, Zavaleta C, Keren S, Vaithilingam S, Bodapati S, Liu Z, et al. 
Carbon nanotubes as photoacoustic molecular imaging agents in living mice. 
Nat Nanotechnol 2008;3:557‑62.
41. Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, et al. 
Involvement of the low‑density lipoprotein receptor‑related protein in 
the transcytosis of the brain delivery vector angiopep‑2. J Neurochem 
2008;106:1534‑44.
42. Ding H, Inoue S, Ljubimov AV, Patil R, Portilla‑Arias J, Hu J, et al. Inhibition of 
brain tumor growth by intravenous poly (beta‑L‑malic acid) nanobioconjugate 
with pH‑dependent drug release [corrected]. Proc Natl Acad Sci U S A 
2010;107:18143‑8.
43. Dougherty JD, Fomchenko EI, Akuffo AA, Schmidt E, Helmy KY, Bazzoli E, 
et al. Candidate pathways for promoting differentiation or quiescence of 
oligodendrocyte progenitor‑like cells in glioma. Cancer Res 2012;72:4856‑68.
44. Faucher L, Guay‑Begin AA, Lagueux J, Cote MF, Petitclerc E, Fortin MA. 
Ultra‑small gadolinium oxide nanoparticles to image brain cancer cells in vivo 
with MRI. Contrast media and molecular imaging 2011;6:209‑18.
45. Fiorentini G, Giovanis P, Rossi S, Dentico P, Paola R, Turrisi G, et al. A phase II 
clinical study on relapsed malignant gliomas treated with electro‑hyperthermia. 
In vivo 2006;20:721‑4.
46. Fogal V, Sugahara KN, Ruoslahti E, Christian S. Cell surface nucleolin antagonist 
causes endothelial cell apoptosis and normalization of tumor vasculature. 
Angiogenesis 2009;12:91‑100.
47. Fukumura D, Jain RK. Tumor microenvironment abnormalities: Causes, 
consequences, and strategies to normalize. J Cell Biochem 2007;101:937‑49.
48. Fulton DS, Urtasun RC, Scott‑Brown I, Johnson ES, Mielke B, Curry B, et al. 
Increasing radiation dose intensity using hyperfractionation in patients with 
malignant glioma. Final report of a prospective phase I‑II dose response study. 
J Neurooncol 1992;14:63‑72.
49. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. 
Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes 
Dev 2007;21:2683‑710.
50. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal 
Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 
2003;42:419‑36.
51. Gaillard PJ, de Boer AG. A novel opportunity for targeted drug delivery to 
the brain. J Control Release 2006;116:e60‑2.
52. Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood‑brain 
barrier. Expert Opin Drug Deliv 2005;2:299‑309.
53. Gannon CJ, Cherukuri P, Yakobson BI, Cognet L, Kanzius JS, Kittrell C, 
et al. Carbon nanotube‑enhanced thermal destruction of cancer cells in a 
noninvasive	radiofrequency	field.	Cancer	2007;110:2654‑65.
54. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, et al. Shape effects of 
filaments	versus	spherical	particles	in	flow	and	drug	delivery.	Nat	Nanotechnol	
2007;2:249‑55.
55. Germano IM, Binello E. Stem cells and gliomas: Past, present, and future. 
J Neurooncol 2014;119:547‑55.
56. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, Taylor CB. 
Selective inductive heating of lymph nodes. Ann Surg 1957;146:596‑606.
57. Giraudeau C, Geffroy F, Meriaux S, Boumezbeur F, Robert P, Port M, et al. 
19F molecular MR imaging for detection of brain tumor angiogenesis: In vivo 
validation using targeted PFOB nanoparticles. Angiogenesis 2013;16:171‑9.
58. Glazer ES, Curley SA. Non‑invasive radiofrequency ablation of malignancies 
mediated by quantum dots, gold nanoparticles and carbon nanotubes. Ther 
Deliv 2011;2:1325‑30.
59.	 Glazer	ES,	Curley	SA.	Radiofrequency	field‑induced	thermal	cytotoxicity	in	
cancer	cells	treated	with	fluorescent	nanoparticles.	Cancer	2010;116:3285‑93.
60. Glazer ES, Massey KL, Zhu C, Curley SA. Pancreatic carcinoma cells are 
susceptible	to	noninvasive	radio	frequency	fields	after	treatment	with	targeted	
gold nanoparticles. Surgery 2010;148:319‑24.
61. Groothuis DR. The blood‑brain and blood‑tumor barriers: A review of 
strategies for increasing drug delivery. Neuro Oncol 2000;2:45‑59.
62. Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, et al. Aptamer‑functionalized 
PEG‑PLGA nanoparticles for enhanced anti‑glioma drug delivery. Biomaterials 
2011;32:8010‑20.
63. Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, 
et al. EGFRvIII antibody‑conjugated iron oxide nanoparticles for magnetic 
resonance imaging‑guided convection‑enhanced delivery and targeted therapy 
of glioblastoma. Cancer Res 2010;70:6303‑12.
64. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to 
enhance radiotherapy in mice. Phys Med Biol 2004;49:N309‑15.
65. Hainfeld JF, Smilowitz HM, O’Connor MJ, Dilmanian FA, Slatkin DN. Gold 
nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine 
2013;8:1601‑9.
66. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC. 
Modeling Adult Gliomas Using RCAS/t‑va Technology. Transl Oncol 
2009;2:89‑95.
67. Harris G, Palosaari T, Magdolenova Z, Mennecozzi M, Gineste JM, Saavedra L, 
et al. Iron oxide nanoparticle toxicity testing using high throughput analysis 
and high content imaging. Nanotoxicology 2013. [Ahead of print]
68. Huang J, Xie J, Chen K, Bu L, Lee S, Cheng Z, et al. HSA coated MnO 
nanoparticles with prominent MRI contrast for tumor imaging. Chem 
Commun 2010;46:6684‑6.
69. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules:  A new 
platform for nanomedicine. Int J Pharm 2009;379:201‑9.
70. Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA. 
Nanotechnology‑based approaches in anticancer research. Int J Nanomed 
2012;7:4391‑408.
71. Jackson H, Muhammad O, Daneshvar H, Nelms J, Popescu A, Vogelbaum MA, 
et al. Quantum dots are phagocytized by macrophages and colocalize with 
experimental gliomas. Neurosurgery 2007;60:524‑9.
72. James JS. DOXIL approved for KS. AIDS treatment news 1995(no 236):6.
73. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. Activating 
gene expression in mammalian cells with promoter‑targeted duplex RNAs. 
Nat Chem Biol 2007;3:166‑73.
74. Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, et al. Spherical 
Nucleic Acid Nanoparticle Conjugates as an RNAi‑Based Therapy for 
Glioblastoma. Sci Transl Med 2013;5:209ra152.
75. Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle‑mediated cellular response 
is size‑dependent. Nat Nanotechnol 2008;3:145‑50.
76. Jin J, Bae KH, Yang H, Lee SJ, Kim H, Kim Y, et al. In Vivo	specific	delivery	of	
c‑Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug 
Chem 2011;22:2568‑72.
77. Jordan A, Maier‑Hauff K. Magnetic nanoparticles for intracranial thermotherapy. 
J Nanosci and Nanotechnol 2007;7:4604‑6.
78. Jordan A, Scholz R, Maier‑Hauff K, van Landeghem FK, Waldoefner N, 
Teichgraeber U, et al. The effect of thermotherapy using magnetic 
nanoparticles on rat malignant glioma. J Neurooncol 2006;78:7‑14.
79. Juillerat‑Jeanneret L. The targeted delivery of cancer drugs across the 
blood‑brain	barrier:	Chemical	modifications	of	drugs	or	drug‑nanoparticles?	
Drug Discov Today 2008;13:1099‑106.
80. Juzenas P, Chen W, Sun YP, Coelho MA, Generalov R, Generalova N, et al. 
Quantum dots and nanoparticles for photodynamic and radiation therapies 
of cancer. Adv Drug Deliv Rev 2008;60:1600‑14.
81. Kang CS, Zhang ZY, Jia ZF, Wang GX, Qiu MZ, Zhou HX, et al. Suppression 
SNI: Neuro-Oncology 2015,  Vol 6, Suppl 1 - A Supplement to Surgical Neurology International 
S56
of EGFR expression by antisense or small interference RNA inhibits U251 
glioma cell growth in vitro and in vivo. Cancer Gene Ther 2006;13:530‑8.
82. Kang MR, Yang G, Place RF, Charisse K, Epstein‑Barash H, Manoharan M, 
et al. Intravesical delivery of small activating RNA formulated into lipid 
nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res 
2012;72:5069‑79.
83. Karabeber H, Huang R, Iacono P, Samii JM, Pitter K, Holland EC, et al. Guiding 
brain tumor resection using surface‑enhanced raman scattering nanoparticles 
and a hand‑held raman scanner. ACS Nano 2014. [Ahead of print].
84. Kaur R, Badea I. Nanodiamonds as novel nanomaterials for biomedical 
applications: Drug delivery and imaging systems. Int J Nanomed 2013;8:203‑20.
85. Kenski DM, Butora G, Willingham AT, Cooper AJ, Fu W, Qi N, et al. 
siRNA‑optimized	Modifications	for	Enhanced	In Vivo Activity. Mol Ther Nucleic 
Acids 2012;1:e5.
86. Kesavan K, Ratliff J, Johnson EW, Dahlberg W, Asara JM, Misra P, et al. Annexin 
A2 is a molecular target for TM601, a peptide with tumor‑targeting and 
anti‑angiogenic effects. The J Biol Chem 2010;285:4366‑74.
87. Kievit FM, Veiseh O, Bhattarai N, Fang C, Gunn JW, Lee D, et al. PEI‑PEG‑Chitosan 
copolymer coated iron oxide nanoparticles for safe gene delivery: Synthesis, 
complexation, and transfection. Adv Funct Mater 2009;19:2244‑51.
88. Kievit FM, Veiseh O, Fang C, Bhattarai N, Lee D, Ellenbogen RG, et al. 
Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to 
glioma. ACS Nano 2010;4:4587‑94.
89. Kievit FM, Zhang M. Surface engineering of iron oxide nanoparticles for 
targeted cancer therapy. Acc Chem Res 2011;44:853‑62.
90. Kim B, Han G, Toley BJ, Kim CK, Rotello VM, Forbes NS. Tuning payload 
delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol 
2010;5:465‑72.
91. Kim TH, Lee S, Chen X. Nanotheranostics for personalized medicine. Expert 
Rev Mol Diagn 2013;13:257‑69.
92. Kircher MF, de la Zerda A, Jokerst JV, Zavaleta CL, Kempen PJ, Mittra E, 
et al. A brain tumor molecular imaging strategy using a new triple‑modality 
MRI‑photoacoustic‑Raman nanoparticle. Nat Med 2012;18:829‑34.
93. Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, et al. 
LDL receptor‑related protein, a multifunctional ApoE receptor, binds 
secreted beta‑amyloid precursor protein and mediates its degradation. Cell 
1995;82:331‑40.
94. Kraft JC, Freeling JP, Wang Z, Ho RJ. Emerging research and clinical 
development trends of liposome and lipid nanoparticle drug delivery systems. 
J Pharm Sci 2014;103:29‑52.
95. Kreuter J. Mechanism of polymeric nanoparticle‑based drug transport across 
the blood‑brain barrier (BBB). J Microencapsul 2013;30:49‑54.
96. Kreuter J. Nanoparticles‑‑a historical perspective. Int J Pharm 2007;331:1‑10.
97. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through 
the blood‑brain barrier with colloidal polymer particles (nanoparticles). Brain 
Res 1995;674:171‑4.
98. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. 
Long‑term survival with glioblastoma multiforme. Brain 2007;130:2596‑606.
99. Kwiatkowska A, Nandhu MS, Behera P, Chiocca EA, Viapiano MS. Strategies 
in gene therapy for glioblastoma. Cancers 2013;5:1271‑305.
100.	 Langer	R.	Biomaterials	and	biotechnology:	From	the	discovery	of	the	first	
angiogenesis inhibitors to the development of controlled drug delivery 
systems and the foundation of tissue engineering. J Biomed Mater Res Part A 
2013;101:2449‑55.
101. Leten C, Struys T, Dresselaers T, Himmelreich U. In vivo and ex vivo assessment 
of the blood brain barrier integrity in different glioblastoma animal models. 
J Neurooncol 2014;119:297‑306.
102. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, et al. Small dsRNAs 
induce transcriptional activation in human cells. Proc Natl Acad Sci U S A 
2006;103:17337‑42.
103. Li ML, Wang JC, Schwartz JA, Gill‑Sharp KL, Stoica G, Wang LV. In‑vivo 
photoacoustic microscopy of nanoshell extravasation from solid tumor 
vasculature. J Biomed Opt 2009;14:010507.
104. Liu L, Ni F, Zhang J, Wang C, Lu X, Guo Z, et al. Thermal analysis in the rat 
glioma model during directly multipoint injection hyperthermia incorporating 
magnetic nanoparticles. J Nanosci Nanotechnol 2011;11:10333‑8.
105. Liu P, Huang Z, Chen Z, Xu R, Wu H, Zang F, et al. Silver nanoparticles: A novel 
radiation sensitizer for glioma? Nanoscale 2013;5:11829‑36.
106. Liu Y, Huang R, Han L, Ke W, Shao K, Ye L, et al. Brain‑targeting gene delivery 
and	cellular	internalization	mechanisms	for	modified	rabies	virus	glycoprotein	
RVG29 nanoparticles. Biomaterials 2009;30:4195‑202.
107. Lu W. Adsorptive‑mediated brain delivery systems. Curr Pharm Biotechnol 
2012;13:2340‑8.
108. Lu W, Tan YZ, Hu KL, Jiang XG. Cationic albumin conjugated pegylated 
nanoparticle with its transcytosis ability and little toxicity against blood‑brain 
barrier. Int J Pharm 2005;295:247‑60.
109. Madhankumar AB, Slagle‑Webb B, Mintz A, Sheehan JM, Connor JR. 
Interleukin‑13 receptor‑targeted nanovesicles are a potential therapy for 
glioblastoma multiforme. Mol Cancer Ther 2006;5:3162‑9.
110. Maeda HG, Fang J. EPR effect and polymeric drugs: A paradigm shift for cancer 
chemotherapy in the 21st century. Adv Polym Sci 2006;193:103‑21.
111. Maier‑Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, et al. 
Intracranial thermotherapy using magnetic nanoparticles combined with 
external beam radiotherapy: Results of a feasibility study on patients with 
glioblastoma multiforme. J Neurooncol 2007;81:53‑60.
112. Maier‑Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, et al. 
Efficacy	and	safety	of	intratumoral	thermotherapy	using	magnetic	iron‑oxide	
nanoparticles combined with external beam radiotherapy on patients with 
recurrent glioblastoma multiforme. J Neurooncol 2011;103:317‑24.
113. Mali P, Yang LH, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA‑Guided 
Human Genome Engineering via Cas9. Science 2013;339:823‑6.
114. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, et al. Epidermal 
growth	factor	receptor‑targeted	immunoliposomes	significantly	enhance	the	
efficacy	of	multiple	anticancer	drugs	in vivo. Cancer Res 2005;65:11631‑8.
115. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in 
cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins 
and the antitumor agent smancs. Cancer Res 1986;46:6387‑92.
116. Mattix B, Moore T, Uvarov O, Pollard S, O’Donnell L, Park K, et al. Effects of 
polymeric nanoparticle surface properties on interaction with brain tumor 
environment. Nano Life 2013;3:1343003.
117. Maurizi L, Sakulkhu U, Gramoun A, Vallee JP, Hofmann H. A fast and 
reproducible method to quantify magnetic nanoparticle biodistribution. 
Analyst 2014;139:1184‑91.
118. Meyers JD, Doane T, Burda C, Basilion JP. Nanoparticles for imaging and 
treating brain cancer. Nanomedicine 2013;8:123‑43.
119. Moan J, Juzenas P. Singlet oxygen in photosensitization. J Environ Pathol Toxicol 
Oncol 2006;25:29‑50.
120. Moan J, Peng Q. An outline of the hundred‑year history of PDT. Anticancer 
Res 2003;23:3591‑600.
121. Mok H, Zhang M. Superparamagnetic iron oxide nanoparticle‑based delivery 
systems for biotherapeutics. Expert Opin Drug Deliv 2013;10:73‑87.
122. Nguyen DN, Mahon KP, Chikh G, Kim P, Chung H, Vicari AP, et al. Lipid‑derived 
nanoparticles for immunostimulatory RNA adjuvant delivery. Proc Natl Acad 
Sci U S A 2012;109:E797‑803.
123. O’Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron 
emitters. Phys Med Biol 1996;41:1973‑92.
124. Oku N, Yamashita M, Katayama Y, Urakami T, Hatanaka K, Shimizu K, et al. PET 
imaging of brain cancer with positron emitter‑labeled liposomes. Int J Pharm 
2011;403:170‑7.
125. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Committee AC. 
The role of cytotoxic chemotherapy in the management of progressive 
glioblastoma: A systematic review and evidence‑based clinical practice 
guideline. J Neurooncol 2014;118:501‑55.
126. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics 
of polymeric nanoparticles. Int J Pharm 2006;307:93‑102.
127. Palanichamy K, Erkkinen M, Chakravarti A. Predictive and prognostic markers 
in human glioblastomas. Curr Treat Options Oncol 2006;7:490‑504.
128. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers 
as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751‑60.
129. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating 
tumor	 targeting	 efficiency	 of	 nanoparticles	 through	 design.	Nano	 Lett	
2009;9:1909‑15.
130. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for 
therapeutic applications. Nat Rev Drug Discov 2010;9:615‑27.
131. Plotkin M, Gneveckow U, Meier‑Hauff K, Amthauer H, Feussner A, Denecke T, 
et al. 18F‑FET PET for planning of thermotherapy using magnetic nanoparticles 
in recurrent glioblastoma. Int J Hyperthermia 2006;22:319‑25.
132. Preiner J, Kodera N, Tang J, Ebner A, Brameshuber M, Blaas D, et al. IgGs are 
 SNI: Neuro-Oncology 2015,  Vol 6, Suppl 1 - A Supplement to Surgical Neurology International
S57
made for walking on bacterial and viral surfaces. Nat Commun 2014;5:4394.
133. Prime KL, Whitesides GM. Self‑assembled organic monolayers‑Model systems 
for studying adsorption of proteins at surfaces. Science 1991;252:1164‑7.
134. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid‑based 
nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit 
Rev Ther Drug Carrier Syst 2009;26:523‑80.
135. Rahman M, Hoh B, Kohler N, Dunbar EM, Murad GJ. The future of glioma 
treatment: Stem cells, nanotechnology and personalized medicine. Future 
Oncol 2012;8:1149‑56.
136. Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, 
Sampson JH, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab 
for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 
2011;117:5351‑8.
137. Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, et al. 
Immunotherapy advances for glioblastoma. Neuro Oncol 2014;16:1441‑58.
138. Ribot E, Bouzier‑Sore AK, Bouchaud V, Miraux S, Delville MH, Franconi JM, 
et al. Microglia used as vehicles for both inducible thymidine kinase gene 
therapy and MRI contrast agents for glioma therapy. Cancer Gene Ther 
2007;14:724‑37.
139. Ribot EJ, Miraux S, Konsman JP, Bouchaud V, Pourtau L, Delville MH, et al. 
In vivo MR tracking of therapeutic microglia to a human glioma model. Nmr 
Biomed 2011;24:1361‑8.
140. Roger M, Clavreul A, Venier‑Julienne MC, Passirani C, Montero‑Menei C, 
Menei P. The potential of combinations of drug‑loaded nanoparticle systems 
and adult stem cells for glioma therapy. Biomaterials 2011;32:2106‑16.
141. Rouge JL, Hao L, Wu XA, Briley WE, Mirkin CA. Spherical nucleic acids as a 
divergent platform for synthesizing RNA–nanoparticle conjugates through 
enzymatic ligation. ACS Nano 2014;8:8837‑43.
142. Rytting M. Peg‑asparaginase for acute lymphoblastic leukemia. Expert Opin 
Biol Ther 2010;10:833‑9.
143. Sander JD, Joung JK. CRISPR‑Cas systems for editing, regulating and targeting 
genomes. Nat Biotechnol 2014;32:347‑55.
144. Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: Focus on 
cancer. Int J Nanomed 2014;9:467‑83.
145. Santos T, Fang X, Chen MT, Wang W, Ferreira R, Jhaveri N, et al. Sequential 
administration of carbon nanotubes and near‑infrared radiation for the 
treatment of gliomas. Front Oncol 2014;4:180.
146. Sarin H, Kanevsky AS, Wu H, Sousa AA, Wilson CM, Aronova MA, et al. 
Physiologic upper limit of pore size in the blood‑tumor barrier of malignant 
solid tumors. J Transl Med 2009;7:51.
147. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. 
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin 
Cancer Res 2008;14:2900‑8.
148. Senpan A, Caruthers SD, Rhee I, Mauro NA, Pan D, Hu G, et al. Conquering 
the dark side: Colloidal iron oxide nanoparticles. ACS Nano 2009;3:3917‑26.
149. Shen Y, Zhou Z, Sui M, Tang J, Xu P, Van Kirk EA, et al. Charge‑reversal 
polyamidoamine dendrimer for cascade nuclear drug delivery. Nanomedicine 
2010;5:1205‑17.
150. Shriver LP, Koudelka KJ, Manchester M. Viral nanoparticles associate with 
regions	 of	 inflammation	 and	 blood	 brain	 barrier	 disruption	 during	CNS	
infection. J Neuroimmunol 2009;211:66‑72.
151. Silva AC, Oliveira TR, Mamani JB, Malheiros SM, Malavolta L, Pavon LF, et al. 
Application of hyperthermia induced by superparamagnetic iron oxide 
nanoparticles in glioma treatment. Int J Nanomed 2011;6:591‑603.
152. Simon LC, Sabliov CM. The effect of nanoparticle properties, detection 
method, delivery route and animal model on poly (lactic‑co‑glycolic) 
acid nanoparticles biodistribution in mice and rats. Drug Metab Rev 
2014;46:128‑41.
153. Stea B, Cetas TC, Cassady JR, Guthkelch AN, Iacono R, Lulu B, et al. Interstitial 
thermoradiotherapy of brain tumors: Preliminary results of a phase I clinical 
trial. Int J Radiat Oncol Biol Phys 1990;19:1463‑71.
154. Stea B, Rossman K, Kittelson J, Shetter A, Hamilton A, Cassady JR. Interstitial 
irradiation versus interstitial thermoradiotherapy for supratentorial 
malignant gliomas: A comparative survival analysis. Int J Radiat Oncol Biol 
Phys 1994;30:591‑600.
155. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, 
et al. Chemotherapy of glioblastoma in rats using doxorubicin‑loaded 
nanoparticles. Int J Cancer 2004;109:759‑67.
156. Stephen ZR, Kievit FM, Veiseh O, Chiarelli PA, Fang C, Wang K, et al. 
Redox‑responsive magnetic nanoparticle for targeted convection‑enhanced 
delivery of O‑benzylguanine to brain tumors. ACS Nano 2014;8:10383‑95.
157. Stephen ZR, Kievit FM, Zhang M. Magnetite nanoparticles for Medical MR 
Imaging. Mater Today 2011;14:330‑8.
158. Stojanov K, Zuhorn IS, Dierckx RA, de Vries EF. Imaging of cells and 
nanoparticles: Implications for drug delivery to the brain. Pharm Res 
2012;29:3213‑34.
159. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. 
Effects of radiotherapy with concomitant and adjuvant temozolomide versus 
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 
5‑year analysis of the EORTC‑NCIC trial. Lancet Oncol 2009;10:459‑66.
160. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. 
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. 
N Engl J Med 2005;352:987‑96.
161. Torres‑Reveron J, Tomasiewicz HC, Shetty A, Amankulor NM, Chiang VL. 
Stereotactic laser induced thermotherapy (LITT): A novel treatment for 
brain lesions regrowing after radiosurgery. J Neurooncol 2013;113:495‑503.
162. Tzeng SY, Green JJ. Therapeutic nanomedicine for brain cancer. Ther Deliv 
2013;4:687‑704.
163. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin‑ and 
transferrin‑receptor‑antibody‑modified	nanoparticles	enable	drug	delivery	
across the blood‑brain barrier (BBB). Eur J Pharm Biopharm 2009;71:251‑6.
164. Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: Nanoparticles 
for drug delivery across the blood‑brain barrier (BBB). J Drug Target 
2011;19:125‑32.
165. van Landeghem FK, Maier‑Hauff K, Jordan A, Hoffmann KT, Gneveckow U, 
Scholz R, et al. Post‑mortem studies in glioblastoma patients treated with 
thermotherapy using magnetic nanoparticles. Biomaterials 2009;30:52‑7.
166. van Rooy I, Mastrobattista E, Storm G, Hennink WE, Schiffelers RM. 
Comparison	of	five	different	targeting	ligands	to	enhance	accumulation	of	
liposomes into the brain. J Control Release 2011;150:30‑6.
167. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, et al. 
Comparison of two superparamagnetic viral‑sized iron oxide particles 
ferumoxides and ferumoxtran‑10 with a gadolinium chelate in imaging 
intracranial tumors. AJNR Am J Neuroradiol 2002;23:510‑9.
168. Veiseh O, Gunn JW, Kievit FM, Sun C, Fang C, Lee JS, et al. Inhibition of 
tumor‑cell invasion with chlorotoxin‑bound superparamagnetic nanoparticles. 
Small 2009;5:256‑64.
169. Veiseh O, Kievit FM, Fang C, Mu N, Jana S, Leung MC, et al. Chlorotoxin bound 
magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA 
delivery. Biomaterials 2010;31:8032‑42.
170. Veiseh O, Kievit FM, Mok H, Ayesh J, Clark C, Fang C, et al. Cell transcytosing 
poly‑arginine coated magnetic nanovector for safe and effective siRNA 
delivery. Biomaterials 2011;32:5717‑25.
171. Veiseh O, Sun C, Fang C, Bhattarai N, Gunn J, Kievit F, et al.	Specific	targeting	
of brain tumors with an optical/magnetic resonance imaging nanoprobe 
across the blood‑brain barrier. Cancer Res 2009;69:6200‑7.
172. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, 
et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic 
gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333‑43.
173. Wang CX, Huang LS, Hou LB, Jiang L, Yan ZT, Wang YL, et al. Antitumor effects 
of polysorbate‑80 coated gemcitabine polybutylcyanoacrylate nanoparticles 
in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor 
model. Brain Res 2009;1261:91‑9.
174. Wang X, Pang Y, Ku G, Xie X, Stoica G, Wang LV. Noninvasive laser‑induced 
photoacoustic tomography for structural and functional in vivo imaging of 
the brain. Nat Biotechnol 2003;21:803‑6.
175. Wankhede M, Bouras A, Kaluzova M, Hadjipanayis CG. Magnetic nanoparticles: 
An emerging technology for malignant brain tumor imaging and therapy. 
Expert Rev Clin Pharmacol 2012;5:173‑86.
176. Weinstein S, Peer D. RNAi nanomedicines: Challenges and opportunities 
within the immune system. Nanotechnology 2010;21:232001.
177. Whitehead KA, Langer R, Anderson DG. Knocking down barriers:  Advances 
in siRNA delivery. Nat Rev Drug Discov 2009;8:129‑38.
178. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake 
of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 
2005;26:2713‑22.
179. Wismeth C, Dudel C, Pascher C, Ramm P, Pietsch T, Hirschmann B, et al. 
Transcranial electro‑hyperthermia combined with alkylating chemotherapy in 
SNI: Neuro-Oncology 2015,  Vol 6, Suppl 1 - A Supplement to Surgical Neurology International 
S58
patients with relapsed high‑grade gliomas: Phase I clinical results. J Neurooncol 
2010;98:395‑405.
180. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, et al. 
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat 
Biotechnol 2007;25:1149‑57.
181. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery 
of CNS therapeutics. Adv Drug Deliv Rev 2012;64:686‑700.
182. Xi G, Robinson E, Mania‑Farnell B, Vanin EF, Shim KW, Takao T, et al. 
Convection‑enhanced delivery of nanodiamond drug delivery platforms for 
intracranial tumor treatment. Nanomedicine 2014;10:381‑91.
183.	 Xin	H,	Sha	X,	Jiang	X,	Zhang	W,	Chen	L,	Fang	X.	Anti‑glioblastoma	efficacy	
and safety of paclitaxel‑loading Angiopep‑conjugated dual targeting PEG‑PCL 
nanoparticles. Biomaterials 2012;33:8167‑76.
184. Xu P, Van Kirk EA, Zhan Y, Murdoch WJ, Radosz M, Shen Y. Targeted 
charge‑reversal nanoparticles for nuclear drug delivery. Angew Chem Int Ed 
Engl 2007;46:4999‑5002.
185. Yang W, Liu SJ, Bai T, Keefe AJ, Zhang L, Ella‑Menye JR, et al. Poly (carboxybetaine) 
nanomaterials	enable	long	circulation	and	prevent	polymer‑specific	antibody	
production. Nano Today 2014;9:10‑6.
186.	 Yi	GQ,	Gu	 B,	Chen	 LK.	The	 safety	 and	 efficacy	 of	magnetic	 nano‑iron	
hyperthermia therapy on rat brain glioma. Tumour Biol 2014;35:2445‑9.
187. Yoshida J, Mizuno M, Fujii M, Kajita Y, Nakahara N, Hatano M, et al. Human 
gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic 
astrocytoma) by in vivo transduction with human interferon beta gene using 
cationic liposomes. Hum Gene Ther 2004;15:77‑86.
188. Yuan Z, Jiang H. Photoacoustic tomography for imaging nanoparticles. Methods 
Mol Biol 2010;624:309‑24.
189. Zhan C, Wei X, Qian J, Feng L, Zhu J, Lu W. Co‑delivery of TRAIL gene enhances 
the anti‑glioblastoma effect of paclitaxel in vitro and in vivo. J Control Release 
2012;160:630‑6.
190. Zhang J, Jin C, He ZZ, Liu J. Numerical simulations on conformable 
laser‑induced interstitial thermotherapy through combined use of multi‑beam 
heating and biodegradable nanoparticles. Lasers Med Sci 2014;29:1505‑16.
191. Zhang J, Shin MC, Yang VC. Magnetic targeting of novel heparinized iron 
oxide nanoparticles evaluated in a 9L‑glioma mouse model. Pharm Res 
2014;31:579‑92.
192. Zhang XD, Wu D, Shen X, Chen J, Sun YM, Liu PX, et al. Size‑dependent 
radiosensitization of PEG‑coated gold nanoparticles for cancer radiation 
therapy. Biomaterials 2012;33:6408‑19.
193. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous 
RNA interference gene therapy targeting the human epidermal growth 
factor receptor prolongs survival in intracranial brain cancer. Clin Cancer 
Res 2004;10:3667‑77.
194. Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with 
an	artificial	virus	gene	delivery	system.	Mol	Ther	2002;6:67‑72.
195. Zhao D, Alizadeh D, Zhang L, Liu W, Farrukh O, Manuel E, et al. Carbon 
nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin 
Cancer Res 2011;17:771‑82.
196. Zhou J, Zhang J, Gao W. Enhanced and selective delivery of enzyme 
therapy to 9L‑glioma tumor via magnetic targeting of PEG‑modified, 
beta‑glucosidase‑conjugated iron oxide nanoparticles. Int J Nanomed 
2014;9:2905‑17.
197. Zhou Z, Sun Y, Shen J, Wei J, Yu C, Kong B, et al. Iron/iron oxide core/shell 
nanoparticles for magnetic targeting MRI and near‑infrared photothermal 
therapy. Biomaterials 2014;35:7470‑8.
198. Zhou ZS, Tang J, Fan M, Van Kirk EA, Murdoch WJ, Radosz M. Charge‑reversal 
drug conjugate for targeted cancer cell nuclear drug delivery. Adv Funct Mater 
2009;19:3580‑9.
